We are live on ! Find out more
RNTX

Rein Therapeutics

29 hedge funds and large institutions have $13.5M invested in Rein Therapeutics in 2024 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

26% more funds holding

Funds holding: 2329 (+6)

23% more capital invested

Capital invested by funds: $11M → $13.5M (+$2.54M)

11.86% less ownership

Funds ownership: 34.53%22.67% (-12%)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
29
Holders Change
+6
Holders Change %
+26.09%
% of All Funds
0.42%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
10
Increased
9
Reduced
3
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$645
HCP
27
Hexagon Capital Partners
Arkansas
$591 +$875 +213 New
GPFA
28
Game Plan Financial Advisors
Ohio
$69 -$103 -25 -50%
AIM
29
Alerce Investment Management
Illinois
-$5.51M -830,466 Closed
Citadel Advisors
30
Citadel Advisors
Florida
-$89.8K -13,810 Closed
IGWM
31
ICA Group Wealth Management
Colorado
-$663 -100 Closed
Wells Fargo
32
Wells Fargo
California
-$206 -31 Closed

RNTX Hedge Fund Activity: Q2 2024 in Review

29 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2024, worth a combined $13.5M — up 23% from $11M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new RNTX positions and 4 closed out — a net gain of 6 holders — while 9 added to existing stakes and 3 trimmed.

The largest buyer was University of Texas/Texas AM Investment Management Co (UTIMCO), opening a new position worth an estimated $7.31M. The largest seller was Alerce Investment Management, exiting entirely with an estimated $5.51M sold.

  • 29 institutional investors held Rein Therapeutics (RNTX) as of Q2 2024, up from 23 in Q1 2024.
  • Funds reported $13.5M of Rein Therapeutics stock for Q2 2024, up 23% quarter-over-quarter.
  • 10 funds opened new Rein Therapeutics positions in Q2 2024 and 4 closed out, a net change of +6 holders.
  • The largest Rein Therapeutics buyer in Q2 2024 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $7.31M added.
  • The largest Rein Therapeutics seller in Q2 2024 was Alerce Investment Management, an estimated $5.51M sold.

Based on aggregated 13F filings for Q2 2024.